• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Study

  2026-07-08

  This study introduces a targeted, intravesical delivery method for p21 mRNA-loaded lipid nanoparticles as a tumor suppressor replacement therapy in bladder cancer. By restoring p21 expression, the approach significantly reduces tumor growth and minimizes systemic toxicity, offering a promising avenue for localized mRNA-based cancer treatment.

• Dovitinib (TKI-258): Advanced Workflows for RTK-Driven Cance

  2026-07-07

  Dovitinib (TKI-258) sets a new benchmark for dissecting receptor tyrosine kinase signaling and apoptosis induction in complex cancer models. This guide delivers actionable protocols, troubleshooting, and strategic insights for maximizing research outcomes using APExBIO’s validated multitargeted RTK inhibitor.

• BMP4-GPX4 Axis Mitigates RGC Ferroptosis in NMDA-Induced Gla

  2026-07-07

  Fang et al. demonstrate that BMP4-driven upregulation of GPX4 reduces ferroptosis and enhances differentiation of transplanted retinal stem cells (RSCs) in a mouse model of high intraocular pressure glaucoma induced by NMDA. This work establishes the BMP4-GPX4 pathway as a promising therapeutic target for neuroprotection and functional restoration in glaucomatous degeneration.

• Evaluating Drug Responses in Cancer: In Vitro Method Advance

  2026-07-06

  Schwartz's dissertation critically examines how in vitro assays measure anti-cancer drug effects, distinguishing between cell proliferation inhibition and cell death. By clarifying assay interpretation, the study improves the reliability of preclinical drug evaluation and informs the use of mechanistic inhibitors such as Flumequine in cancer biology.

• Antibacterial Drug Use and Resistance in Psychiatric Hospita

  2026-07-06

  This study provides a comprehensive retrospective analysis of antibacterial drug use and associated resistance patterns in a psychiatric hospital during the COVID-19 epidemic. The findings highlight a generally rational antibiotic usage profile but reveal concerning trends in rising bacterial resistance, underscoring the critical need for enhanced monitoring and stewardship in psychiatric settings.

• Carvedilol in Regenerative Hematology: Mechanisms and Assay

  2026-07-05

  Explore how Carvedilol, a potent β-adrenergic receptor antagonist, uniquely modulates hematopoietic regeneration and vascular assays. This article offers a deep, evidence-driven analysis with practical guidance for advanced research applications.

• Capecitabine in Tumor-Targeted Drug Delivery: Protocols & In

  2026-07-04

  Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is transforming preclinical oncology research by enabling tumor-selective apoptosis studies and physiologically relevant drug response modeling in organoid and assembloid systems. This guide highlights actionable protocols, troubleshooting, and best practices for leveraging Capecitabine’s unique enzymatic activation and solubility profile in advanced in vitro workflows.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Studies

  2026-07-03

  Masitinib (AB1010) addresses the need for selective inhibition of KIT and PDGFR kinases in cancer biology, mastocytosis, and inflammatory disease research. It is unsuitable for workflows requiring broad-spectrum kinase inhibition or aqueous/ethanol compatibility, and is best suited to DMSO-based protocols targeting KIT signaling pathways.

• Targeted Inhibition of SPP1 in Tumor Macrophages Reduces Tum

  2026-07-03

  This study identifies and validates small molecule inhibitors targeting SPP1 in tumor-associated macrophages (TAM), demonstrating effective tumor regression in murine models. The findings provide a framework for developing TAM-specific therapeutic strategies, with potential implications for immuno-oncology research workflows.

• RSV NS3 Manipulates Host Kinase Signaling to Fine-Tune Patho

  2026-07-02

  Zhuang et al. (2025) reveal how Rice stripe virus (RSV) NS3 protein exploits the host OsSnRK3.25-OsCBL1/3-OsRBOHF signaling pathway to dynamically balance viral pathogenicity and transmission. This mechanistic insight advances our understanding of plant-virus-vector co-evolution and highlights precise molecular strategies of viral adaptation.

• 17-AAG (Tanespimycin): HSP90 Inhibition in Cancer Research

  2026-07-02

  17-AAG (Tanespimycin) is a potent synthetic inhibitor of HSP90, enabling selective degradation of oncogenic proteins in cancer research. It demonstrates nanomolar activity across multiple tumor models and is a key tool for dissecting apoptosis and signaling pathway dynamics. Supplied by APExBIO, its robust profile supports both in vitro and in vivo mechanistic studies.

• Amyloid Beta-peptide (25-35): Optimizing Neurotoxicity Model

  2026-07-01

  Amyloid Beta-peptide (25-35) (Aβ25-35) is the gold standard for modeling Alzheimer's disease-related neurotoxicity, enabling precise control over microglial polarization and amyloid aggregation in vitro. This article delivers actionable protocols, troubleshooting guidance, and workflow innovations grounded in the latest mechanistic discoveries.

• Lenalidomide (CC-5013): Mechanistic Precision in Immune Modu

  2026-07-01

  Explore the multifaceted mechanisms of Lenalidomide (CC-5013) as an antineoplastic and immune system activation agent. This article uniquely dissects the translational importance of recent epigenetic-immune findings, offering guidance for advanced myeloma research workflows.

• Anlotinib Hydrochloride in IADSRCT: Case Evidence and Angiog

  2026-06-30

  This article examines the first documented use of anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT), a rare and aggressive malignancy. The referenced case study demonstrates rapid tumor response and manageable toxicity, offering a new therapeutic perspective for this challenging cancer subtype.

• GPX4-Driven Glutathione Metabolism and Platinum Resistance i

  2026-06-30

  This article examines how glutathione peroxidase 4 (GPX4)-dependent glutathione consumption underpins acquired resistance to platinum chemotherapy in lung cancer-derived brain metastasis. The reference study reveals Wnt/NR2F2 signaling as a pivotal regulator of GPX4 expression, providing mechanistic insight and highlighting new targets for overcoming chemoresistance in metastatic lung cancer.

16542 records 1/1103 page Next 12345 下5页 Last page